• This is Vicore
    • Our story
    • Our ambition and strategic priorities
    • Collaborations and partnerships
    • Scientific Advisors
    • Senior Leadership Team
    • Board of Directors
  • Science
    • Scientific rationale
    • ATRAG MoA in IPF
    • Intellectual property and orphan drug designation
    • Publications
      • Key publications
      • Posters
  • Our programs
    • Pipeline
    • ASPIRE IPF Ph2b trial
    • Rare lung diseases
      • Buloxibutid (C21) – IPF
      • Almee – PF anxiety
    • Future ATRAG indications
    • Our drug discovery engine
  • Almee™
  • Career
    • Our collaborative business model
    • Open positions
    • Contact
  • Media
    • Press releases (ENG)
    • Pressmeddelanden (SE)
    • Image bank
  • Investors
    • Investors
      • Overview
      • Press releases
      • Rights Issue, September 2024
      • The share
      • Financial reports
      • Financial calendar
      • Events & Presentations
      • Corporate governance
      • Image bank
      • Investor Relations contact
    • Investerare (SE)
      • Översikt
      • Pressmeddelanden
      • Företrädesemission September 2024
      • Aktien
      • Finansiella rapporter
      • Finansiell kalender
      • Events & Presentationer
      • Bolagsstyrning
      • Bolagsstämma
      • Bildbank
      • Investerarkontakt
  • Patients and caregivers
    • IPF
      • Background
      • Patient stories
      • Patient advocacy organizations
    • Transparency
    • Expanded Access Policy
logo
  • This is Vicore
    • Our story
    • Our ambition and strategic priorities
    • Collaborations and partnerships
    • Scientific Advisors
    • Senior Leadership Team
    • Board of Directors
  • Science
    • Scientific rationale
    • ATRAG MoA in IPF
    • Intellectual property and orphan drug designation
    • Publications
      • Key publications
      • Posters
  • Our programs
    • Pipeline
    • ASPIRE IPF Ph2b trial
    • Rare lung diseases
      • Buloxibutid (C21) – IPF
      • Almee – PF anxiety
    • Future ATRAG indications
    • Our drug discovery engine
Almee™
  • Career
    • Our collaborative business model
    • Open positions
    • Contact
  • Media
    • Press releases (ENG)
    • Pressmeddelanden (SE)
    • Image bank
  • Investors
    • Investors
      • Overview
      • Press releases
      • Rights Issue, September 2024
      • The share
      • Financial reports
      • Financial calendar
      • Events & Presentations
      • Corporate governance
      • Image bank
      • Investor Relations contact
    • Investerare (SE)
      • Översikt
      • Pressmeddelanden
      • Företrädesemission September 2024
      • Aktien
      • Finansiella rapporter
      • Finansiell kalender
      • Events & Presentationer
      • Bolagsstyrning
      • Bolagsstämma
      • Bildbank
      • Investerarkontakt
  • Patients and caregivers
    • IPF
      • Background
      • Patient stories
      • Patient advocacy organizations
    • Transparency
    • Expanded Access Policy
logo
Home / Investors / Corporate governance / Corporate governance reports
Overview Press releases Rights Issue, September 2024
  • The share
    • Share monitor
    • Shareholders
    • Ownership board and management
    • Share issues
    • Share capital development
    • Analyst coverage
    • Listing prospectus
Financial reports Financial calendar Events & Presentations
  • Corporate governance
    • Corporate governance reports
    • General meeting
    • Nomination Committee
    • Board of Directors
    • Audit Committee
    • Remuneration Committee
    • Scientific committee
    • Management
    • Remuneration and incentives
    • Auditors
    • Articles of association
Image bank Subscribe to press releases Investor Relations contact

Corporate governance reports

Corporate governance report 2024

The auditor’s opinion on the corporate governance report 2024

Corporate governance report 2023

The auditor’s opinion on the corporate governance report 2023

Corporate governance report 2022

The auditor’s opinion on the corporate governance report 2022

Corporate governance report 2021

The auditor’s opinion on the corporate governance report 2021

Corporate governance report 2020

The auditor’s opinion on the corporate governance report 2020

Corporate governance report 2019

The auditor’s opinion on the corporate governance report 2019

logo
Vicore Pharma’s offices

Kornhamnstorg 53
SE-111 27 Stockholm, Sweden

Agern Allé 5A
DK-2970 Hørsholm, Denmark

Cambridge Innovation Center
14th floor, One Broadway, Cambridge
MA 02142, USA

We'd love to hear from you!
Phone: +46 (0) 31 788 05 60 Mail: info@vicorepharma.com
Billing and mailing address:

Vicore Pharma
Postbox 14
414 52 Gothenburg, Sweden

Quick links
Contact Subscribe to press releases Privacy Policy Cookies